MRNA shares pull back after the biotech firm names Michael McDonnell, a veteran financial leader, to its board and audit committee.
Moderna Inc. appointed Michael McDonnell to its board of directors, effective July 8, 2026. McDonnell, who will also join the audit committee, brings over 30 years of financial leadership experience in life sciences and technology sectors.
The announcement comes as MRNA shares recently hit a 52-week high. Prior to this appointment, Moderna’s board consisted of nine members, with no recent changes reported in the past year.
Moderna’s stock retreated slightly following the news, trimming gains from its recent peak.